We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
In an effort to lower prescription drug spending, China is slashing prices for three drugs by more than 50 percent, a move that will hit both GlaxoSmithKline and AstraZeneca in the wallet. Read More
GlaxoSmithKline is appealing a $54 million fine from the UK’s Competitions and Market Authority over pay-for-delay allegations, contending the company’s conduct was “objectively justified.” Read More
UK regulators have fined Pfizer $14,000 for failing to explain a questionable claim meant to justify price increases on the generic seizure medication Epanutin. Read More
Despite grave doubts, an Indian high court judge is allowing two drugmakers to market and produce contested biosimilars of Roche’s breast cancer therapy Herceptin. Read More
It has been a successful month in the UK for French drug giant Sanofi, with the National Institute for Health and Care Excellence backing two of its drugs. Read More
MiMedx is suing wound-treatment competitor Osiris Therapeutics, accusing it of falsely claiming in a press release that its biologic is superior to MiMedx’s product. Read More
Amgen is suing generics maker Sandoz, claiming that Sandoz’s attempts to market a biosimilar for the blockbuster bone marrow drug Neulasta infringes on two of its patents for the drug. Read More